bioMérieux S.A. (EPA:BIM)

Market Cap	11.12B -18.0%
Revenue (ttm)	4.12B +8.3%
Net Income	377.90M -8.1%
EPS	3.17 -8.6%
Shares Out	118.07M
PE Ratio	29.72
Forward PE	19.64
Dividend	0.90 (0.96%)
Ex-Dividend Date	Jun 9, 2025

Volume	35,476
Average Volume	139,738
Open	94.50
Previous Close	94.20
Day's Range	94.00 - 94.60
52-Week Range	91.85 - 128.30
Beta	0.66
RSI	34.22
Earnings Date	Feb 27, 2026

About bioMérieux

bioMérieux S.A. develops, manufactures, and markets in vitro diagnostic solutions for infectious diseases in France, Europe, Africa, the Middle East, North and South America, the Asia Pacific, and internationally. It operates through Clinical Applications and Industrial Applications segments. The company offers CHROMID RANGE, a chromogen culture media; air, surface, and water monitoring systems; BACT/ALERT VIRTUO, a blood sample culture system; BIOFIRE, a multiplex polymerase chain reaction system (PCR); BIOFIRE SPOTFIRE, a lowplex PCR point-of...

• Industry: Diagnostics & Research
• Sector: Healthcare
• Founded: 1963
• Employees: 14,754
• Stock Exchange: Euronext Paris
• Ticker Symbol: BIM

Financial Performance

In 2024, bioMérieux's revenue was 3.98 billion, an increase of 8.31% compared to the previous year's 3.67 billion. Earnings were 432.20 million, an increase of 20.86%.